M. Green

发表

Clonal hematopoiesis is associated with increased toxicity in large B-cell lymphoma patients treated with chimeric antigen receptor T cell therapy

C. Flowers, E. Shpall, A. Futreal, 2021 .

A cross‐linker‐sensitive myeloid leukemia cell line from a 2‐year‐old boy with severe Fanconi anemia and biallelic FANCD1/BRCA2 mutations

G. M. Taylor, J. Clayton-Smith, Q. Waisfisz, 2005, Genes, chromosomes & cancer.

Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma

Y. Oki, S. Tewari, Yang Lu, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma

Jennifer B Dennison, S. Hanash, C. Flowers, 2022, Cell reports. Medicine.

Activated B cells suppress T-cell function through metabolic competition

Tamara J Laskowski, J. Wargo, Fang Wang, 2022, Journal for ImmunoTherapy of Cancer.

Advancing CAR T cell therapy through the use of multidimensional omics data

Ying Jing, Ya-Min Chen, M. Green, 2023, Nature Reviews Clinical Oncology.

Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression

C. Flowers, Guangchun Han, Linghua Wang, 2022, Blood cancer discovery.

Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy

Hannah C. Beird, P. Sharma, K. Tomczak, 2021, Nature Communications.

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Shaojun Zhang, Guangchun Han, Linghua Wang, 2020, Nature Medicine.

Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma

W. C. Chan, A. Alizadeh, I. Lossos, 2014, Nature Communications.

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

K. Pradhan, S. Demo, A. Verma, 2023, Research square.

Clinical Utility of Monoclonal Antibodies in the Phenotyping of Acute and Chronic Lymphocytic Leukemia

Mark R. Green, A. Yu, R. Dillman, 1983 .

Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies

M. Mikuła, D. Nowis, J. Gołąb, 2021, Cancer Research.

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

C. Flowers, Linghua Wang, S. Parmar, 2022, Blood.

Clinical e ﬃ cacy of anakinra to mitigate CAR T-cell therapy – associated toxicity in large B-cell lymphoma

E. Shpall, J. Westin, S. Neelapu, 2020 .

Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma.

C. Flowers, G. Garcia-Manero, E. Shpall, 2022, Blood cancer discovery.

A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL

A. Alizadeh, D. Kurtz, Y. Oki, 2022, Blood advances.

Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

Mingyao Li, A. Jazaeri, J. Ajani, 2023, Nature Medicine.

Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells

Linghua Wang, Koichi Takahashi, J. Westin, 2023, Cell reports. Medicine.

CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin

Linghua Wang, S. Sidhu, V. Cortez-Retamozo, 2023, bioRxiv.

A Phase I Study of Prophylactic Anakinra to Mitigate ICANS in Patients with Large B-cell Lymphoma.

E. Shpall, D. Chihara, J. Westin, 2023, Blood advances.

Borrowing Transcriptional Kinases to Activate Apoptosis

Tinghu Zhang, A. Krokhotin, S. Hinshaw, 2023, bioRxiv.